BACKGROUND: The HER2 655 A>G genetic variant has recently been associated with trastuzumab-induced cardiotoxicity in HER2 breast cancer patients. Considering previous results, the aim of our study was to validate the role of this polymorphism as a predictor of the cardiac toxicity of trastuzumab in breast cancer patients. METHODS: Our study population was composed of 78 HER2 breast cancer patients receiving trastuzumab. The HER2 655 A>G (rs1136201) genetic variant was genotyped using TaqMan allelic discrimination technology. Patients were classified on the basis of the occurrence of cardiotoxic events or the absence of cardiotoxic events during 1 year after the first infusion. RESULTS: The HER2 655 A>G polymorphism was significantly associated with cardiotoxicity: AG versus AA [P=0.012, odds ratio (OR)=5.12, 95% confidence interval (CI) 1.43-18.36], AG+GG versus AA (P=0.01, OR=5.72, 95% CI 1.50-21.76), AG versus AA+GG (P=0.005, OR=7.17, 95% CI 1.82-28.29). A meta-analysis combining these data with the results from previous studies confirmed this association. CONCLUSION: Our results support the role of the HER2 655 A>G polymorphism as a genetic marker of trastuzumab-induced cardiotoxicity in HER2-positive breast cancer patients.
BACKGROUND: The HER2 655 A>G genetic variant has recently been associated with trastuzumab-induced cardiotoxicity in HER2 breast cancerpatients. Considering previous results, the aim of our study was to validate the role of this polymorphism as a predictor of the cardiac toxicity of trastuzumab in breast cancerpatients. METHODS: Our study population was composed of 78 HER2breast cancerpatients receiving trastuzumab. The HER2 655 A>G (rs1136201) genetic variant was genotyped using TaqMan allelic discrimination technology. Patients were classified on the basis of the occurrence of cardiotoxic events or the absence of cardiotoxic events during 1 year after the first infusion. RESULTS: The HER2 655 A>G polymorphism was significantly associated with cardiotoxicity: AG versus AA [P=0.012, odds ratio (OR)=5.12, 95% confidence interval (CI) 1.43-18.36], AG+GG versus AA (P=0.01, OR=5.72, 95% CI 1.50-21.76), AG versus AA+GG (P=0.005, OR=7.17, 95% CI 1.82-28.29). A meta-analysis combining these data with the results from previous studies confirmed this association. CONCLUSION: Our results support the role of the HER2 655 A>G polymorphism as a genetic marker of trastuzumab-induced cardiotoxicity in HER2-positive breast cancerpatients.
Authors: Daniel J Serie; Julia E Crook; Brian M Necela; Travis J Dockter; Xue Wang; Yan W Asmann; DeLisa Fairweather; Katelyn A Bruno; Gerardo Colon-Otero; Edith A Perez; E Aubrey Thompson; Nadine Norton Journal: Pharmacogenet Genomics Date: 2017-10 Impact factor: 2.089
Authors: Marco Bruno Morelli; Chiara Bongiovanni; Silvia Da Pra; Carmen Miano; Francesca Sacchi; Mattia Lauriola; Gabriele D'Uva Journal: Front Cardiovasc Med Date: 2022-04-15
Authors: Mohammed Al-Sadawi; Yasin Hussain; Robert S Copeland-Halperin; Jonathan N Tobin; Chaya S Moskowitz; Chau T Dang; Jennifer E Liu; Richard M Steingart; Michelle N Johnson; Anthony F Yu Journal: Am J Cardiol Date: 2021-02-20 Impact factor: 2.778